DONOR MATCHING FOR
STEM CELL TRANSPLANT
HLA matching determines GVHD risk and graft success. Matched sibling (25% per sibling), matched unrelated (Be The Match 40M+ donors), haploidentical (every patient has one), cord blood. Racial disparities in registry representation are real.
analyticsAt a Glance
- check_circleHLA (human leukocyte antigen) matching is critical to reduce graft-versus-host disease (GvHD)
- check_circleA 10/10 HLA matched unrelated donor is the gold standard when no sibling match is available
- check_circleHaploidentical (half-matched) transplants from parents or children are now widely available
- check_circleGlobal registries (WMDA, Be The Match) and cord blood banks expand the search pool
What This Means for Patients
Matched sibling: 25% per sibling probability, gold standard. MUD: Be The Match 40M+ donors, 75-80% of White patients find match, 50-60% for non-White. Haploidentical: every patient has one (biological parent), PTCy revolutionised outcomes. Cord blood: less stringent matching, slower engraftment. Sea
Key Insights
Understanding this topic is essential for informed transplant decisions and productive conversations with the transplant team.
Clinical Relevance
Directly impacts transplant planning, donor selection, conditioning decisions, and understanding of what the procedure accomplishes for your specific disease.
For Patients and Families
Knowledge enables better-informed questions, realistic expectations, and active participation in transplant decisions alongside the clinical team.
Benefits and Limitations
Benefits
- Allogeneic HSCT provides documented cures for specific haematologic malignancies
- Haploidentical and RIC approaches expanded the eligible patient population
- Decades of randomised trial data support disease-specific transplant indications
Limitations
- Treatment-related mortality is a real risk requiring specialist centre expertise
- GVHD remains a significant complication of allogeneic transplant
- Full recovery timeline is longer than most patients initially expect
Frequently Asked Questions
About This Topic
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Evaluating Stem Cell Transplant Options?
CancerFax connects patients with specialist transplant centres, donor matching, and comprehensive evaluation for haematologic malignancies and bone marrow failure conditions.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.